Semaglutide was selected for Medicare drug price negotiation in 2025, with a negotiated price set to take effect in 2027 but that negotiated price applies to diabetes and cardiovascular indications covered under current Medicare statute, not to obesity, which remains statutorily excluded
Current Gaps in Research on Semaglutide and Urinary Symptoms While semaglutide has been widely studied for its benefits in blood sugar control and weight management, there is limited data on its impact on urinary function
Spicer JD, Shewale JB, Bott MJ, Jones DR, Vaporciyan AA, Darling GE, Swisher SG , Sepesi B
Exp Neurol 2008
Otherwise, due to the nature of research compounds, we dont accept returns once shipped
doi: 10.3389/fphar.2025.1632924 Received 21 May 2025 Accepted 30 June 2025 Published 16 July 2025 Volume 16 - 2025 Edited by Domenico Mattoscio, University of Studies G